Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT00782002 Completed - Clinical trials for Advanced Solid Tumors

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

Start date: July 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if IMC-18F1 is safe for patients, and also to determine the best dose of IMC-18F1 to give to patients.

NCT ID: NCT00750425 Completed - Clinical trials for Advanced Solid Tumors

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Start date: August 2008
Phase: Phase 1
Study type: Interventional

Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.

NCT ID: NCT00747474 Completed - Clinical trials for Advanced Solid Tumors

Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find a safe and tolerable dose of Lipotecan® when administered to patients with advanced solid tumors.

NCT ID: NCT00739453 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Start date: October 23, 2008
Phase: Phase 1
Study type: Interventional

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib

NCT ID: NCT00734305 Completed - Clinical trials for Advanced Solid Tumors

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.

NCT ID: NCT00733187 Completed - Clinical trials for Advanced Solid Tumors

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Start date: February 2009
Phase: Phase 1
Study type: Interventional

To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.

NCT ID: NCT00730470 Completed - Clinical trials for Advanced Solid Tumors

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Start date: August 2008
Phase: Phase 1
Study type: Interventional

This is a Phase 1 clinical study to investigate the safety, pharmacokinetics, and pharmacodynamics of U3-1287 (AMG 888), a fully human monoclonal antibody targeting the HER3 receptor, in patients with advanced solid tumors. Eligible patients will have disease that is refractory or resistant to standard treatments or for which no standard therapy exists. The study will be conducted in two parts; a dose escalation (Part 1) and a dose expansion (Part 2). The hypothesis for this study is that U3-1287 (AMG888) will be safe and well tolerated in patients with advanced solid tumors and will show initial evidence of anti-tumor activity.

NCT ID: NCT00726583 Completed - Clinical trials for Advanced Solid Tumors

Phase I Trial of Oral PX-866

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.

NCT ID: NCT00725933 Completed - Clinical trials for Advanced Solid Tumors

Administration of BIIB028 to Subjects With Solid Tumors

Start date: June 2008
Phase: Phase 1
Study type: Interventional

Safety and Tolerability of BIIB028

NCT ID: NCT00712504 Completed - Clinical trials for Non Small Cell Lung Cancer

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Start date: July 2004
Phase: Phase 1
Study type: Interventional

This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.